Mont-Saint-Guibert, Belgium - Celyad (Euronext Brussels and Paris, and NASDAQ: CYAD), a leader in the discovery and development of engineered cell therapies, with clinical programs in cardiovascular diseases and immuno-oncology, today announced appointment of Dr. Hinrich Abken, Dr. Scott Antonia, Dr. Marco Davila, Dr. Stéphane Depil, Dr. Marc Ernstoff, Dr. David Edward Gilham, Dr. Sebastian Kobold, Dr. Daniel Olive, Dr. Charles Sentman and Dr. Jeffrey S. Weber to the Company’s Scientific Advisory Board.

Dr. Christian Homsy, CEO of Celyad: “We are proud to have gathered such an accomplished team of international immuno-oncology experts to our Scientific Advisory Board. Each member has dedicated their career to landmark scientific achievements that have advanced the field of immunotherapy for cancer treatment. It is of paramount importance for Celyad to surround itself with thought leaders that will help the Company translate pioneering technology into transformative therapies that will change the lives of cancer patients”.

Dr. Frédéric Lehmann, Head of Immuno-Oncology at Celyad:"We are honored to collaborate with these internationally renowned specialists and to cross-fertilize their scientific expertise in immuno-oncology, in clinical development and in cell therapy to develop our NKR-T platform. Their collective knowledge and guidance will contribute to make the most of Celyad’s unique therapeutic approach and potentially open the path to new treatment options for cancer patients”.

The new members of the Scientific Advisory Board include:

  • Dr. Hinrich Abken is Professor for Genetics & Immunology at CMMC (Center for Molecular Medicine Cologne) at the University of Cologne and Dept of Internal Medicine, Oncology?Hematology at the University Hospital Cologne where he is working towards the development of adoptive cell therapy of malignant diseases using engineered
    T-cells. Dr. Abken's group is internationally leading in pre?clinical research of adoptive therapy with T-cells engineered with chimeric antigen receptors.
  • Dr. Scott Antonia is the Department Chair of the Thoracic Oncology Department at the H. Lee Moffitt Cancer Center and Research Institute in Tampa, Florida. He is also a Professor of Oncologic Sciences at the University of South Florida College of Medicine in Tampa. 
    Dr. Antonia’s work focuses on translational research. Using his molecular biology and cellular background in the development of immunotherapeutic strategies for the treatment of cancer patients, he has developed strategies designed to thwart the immunosuppressive mechanisms used by tumors to evade T-cell mediated rejection.
  • Dr. Marco Davila is a medical oncologist that specializes in both clinical and laboratory research in the treatment of patients with hematologic malignancies.  He is Associate Member in the Blood and Marrow Transplantation and Immunology Departments at the Moffitt Cancer Center, University of South Florida. Dr. Davila's laboratory develops gene-engineered cell therapies that target and kill cancerous cells in animal models of hematologic malignancies and was the Principal Investigator of a clinical trial using genetically engineered T cells targeted against malignant B cells. 
  • Dr. Stéphane Depil is onco-hematologist at Léon Bérard Cancer Center and Associate Professor at University Claude Bernard Lyon I, adjunct Professor at UCBL and CEO of Netris Pharma.  Dr Depil has significant expertise in conducting pre-clinical and clinical development in oncology as the former head of Oncology R&D at Servier.
  • Dr. Marc Ernstoff is a medical oncologist, professor and chief of the Division of Hematology/Oncology in the Department of Medicine in the Jacobs School of Medicine and Biomedical Sciences at the University at Buffalo (UB). Over the past 30 years, Dr. Ernstoff has focused his research on expanding understanding of the immunobiology of human cancer and the development of new immune therapies for melanoma, renal cell carcinoma and glioblastoma multiforme.
  • Dr. David Edward Gilham is Senior Lecturer Clinical and Experimental Immunotherapy Group Director of the Institute of Cancer Sciences, Manchester.  His group focuses upon developing immunotherapies for the treatment of cancer which include the exploitation of chimeric antigen receptors and recombinant T cell receptors to re-direct the effector functions of T cells, which are then used in adoptive transfer studies.
  • Dr. Sebastian Koboldis Professor at the Medical Center of the University of Munich and Senior Academic Assistant. He is also Deputy Head of the Immunopharmacology group at Ludwig-Maximilians University of Munich. His research aims to develop new proteins that are intended to modulate the function of T-cells of the human immune system and enable them to destroy specifically and efficiently cancer cells.
    • Dr. Daniel Olive is Professor of Immunology at Aix Marseille University; he is also in charge of the « Immunity and Cancer » research team of INSERM UMR1068 of Marseille Cancer Research Center (Institut Paoli Calmettes). He is the head of the first IBiSA Platform dedicated to Cancer Immunomonitoring Platform and has been a pioneer and leader in the co-signalling field since 1990. His work is dedicated to tumor immunology with a major emphasis on innate immunity and co-signalling molecules.
    • Dr. Charles L. Sentman is a Professor of Microbiology & Immunology and the Director of the Center for Synthetic Immunity at the Geisel School of Medicine at Dartmouth. In addition to academic research, he is a Scientific Founder for Celdara Medical LLC (Lebanon, NH) and inventor of CM-CS1. He has expertise in natural killer cell biology, T cells, immunotherapy, chimeric antigen receptors, bispecific antibodies, and immuno-oncology.
    • Dr. Jeffrey S. Weber is Deputy Director at the Laura and Isaac Perlmutter Cancer Center at the NYU Langone Medical Center and professor of Medicine at NYU and head of Experimental Therapeutics at the Perlmutter Cancer Center. He is a translational clinician-scientist and clinical trialist with an interest in Immuno-Oncology and the development of new treatment strategies for patients with melanoma. Dr. Weber was the principal investigator of the first trial that demonstrated benefit for PD-1 blocking antibodies in melanoma patients that had failed ipilimumab. He was also the first investigator who demonstrated that PD-1 blocking antibodies had encouraging activity in resected melanoma patients.

Download press release(s)

Press release

430.40 Ko

Celyad will present its NKR-2 immuno-oncology clinical program at 2016 ASCO Annual Meeting

Next News

Celyad will present its NKR-2 immuno-oncology clinical program at 2016 ASCO Annual Meeting